Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD）

Phase 2

Completed

• Conditions: Hypercholesterolemia
• Interventions: Drug: Ezetimibe 10mg; Drug: HSK31679 low dose; Drug: HSK31679 medium dose; Drug: Placebo; Drug: HSK31679 high dose

• Registration Number: NCT05795517
• Lead Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Brief Summary

The purpose of this study is to assess the efficacy and safety of HSK31679 tablets compared with placebo in reducing low-density lipoprotein cholesterol (LDL-C) and MRI-PDFF after 12 weeks of treatment in patients with hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-03-09
• Study First Submitted QC: 2023-03-20
• Study First Posted: 2023-04-03
• Study Start: 2023-04-26
• Primary Completion: 2024-02-20
• Study Completion: 2024-03-01
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-08
• Last Update Posted: 2024-04-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 210

Inclusion Criteria

1. Must be willing to participate in the study and provide written informed consent.
2. Male or female aged 18 ≤ age < 65 at the time of signing the informed consent.
3. At the time of screening, patients who had not received lipid-regulation therapy within 6 weeks had fasting LDL-C≥3.34mmol/L（130mg/dL）.
4. (BMI) ≥18kg/m2 and female subjects ≥45.0 kg and male subjects ≥50.0 kg.
5. During screening, fasting triglyceride (TG) <5.65 mmol/L.
6. During screening,MRI-PDFF≥8%.
7. Weight changes≤5% in the 4 weeks prior to screening.

Exclusion Criteria

1. Did not discontinue any lipid-regulating therapy or any drug or supplement that may affect lipid levels 6 weeks before randomization or is expected to do so during the study period.

2. Homozygous familial hypercholesterolemia (HoFH) was diagnosed by genetic or clinical criteria.

3. Dyslipidemia caused by other diseases or drugs, such as rheumatoid arthritis, nephrotic syndrome, Cushing's syndrome, hypothyroidism, renal failure, systemic lupus erythematosus, glycogen accumulation, myeloma, lipodystrophy, acute porphyria, polycystic ovarian syndrome, etc

4. Before screening, LDL-C plasma exchange was performed within 12 months.

5. In the past, PCSK9 inhibitors, Lomitapide and Mipomersen were used for treatment.

6. uncontrolled hypertension had systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg at screening/baseline.

7. type 1 diabetes, or newly diagnosed type 2 diabetes within 1 month, or poorly controlled type 2 diabetes, or who could not maintain the same hypoglycemic regimen during the study.

8. Stroke or transient ischemic attack (TIA), acute coronary syndrome, stable angina attack, severe deep vein thrombosis, or pulmonary embolism occurred in the 12 months prior to screening.

9. Major surgery (including but not limited to: coronary or other revascularization, coronary artery bypass surgery, and transplantation) within 12 months prior to screening or planned during the study period.

10. Chronic systemic disease or history, including but not limited to

    1. Have a serious cardiopulmonary disease or history,Neurological disease or history,Autoimmune disease,Chronic digestive disease or history
    2. Have thyroid disease or symptomatic abnormalities in thyroid function tests (e.g., thyroid stimulating hormone (TSH) < 1.0 x lower limit of normal (LLN) or > 1.5 x upper limit of normal (ULN))
    3. History of malignancy (excluding cured basal cell carcinoma of the skin, carcinoma in situ, and papillary thyroid carcinoma) or history of antitumor therapy within 5 years prior to screening
    4. Disease or medical history assessed by the investigator as likely to affect the study

11. Bariatric surgery within 12 months at the time of screening

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ezetimibe	Ezetimibe 10mg	-
HSK31679 low dose	HSK31679 low dose	-
HSK31679 medium dose	HSK31679 medium dose	-
Placebo	Placebo	-
HSK31679 high dose	HSK31679 high dose	-

Primary Outcome Measures

Name	Time	Method
Percentage change in MRI-PDFF from baseline at 12 week；	Baseline and Week 12	Percentage change of MRI-PDFF(change in liver fat content by nuclear magnetic resonance - Proton Density Fat Fraction) from baseline after 12 weeks of treatment;
Percentage change in LDL-C from baseline at 12 week;	Baseline and Week 12	Percentage change in fasting low-density lipoprotein cholesterol (LDL-C) from baseline after 12 weeks of treatment;

Secondary Outcome Measures

Name	Time	Method
Proportion of patients with LDL-C<3.34mmol/L（<130mg/dL）	Baseline and Week 12	After 12 weeks of treatment, the proportion of patients with LDL-C\<3.34mmol/L（\<130mg/dL）
Percentage change of fasting TG from baseline;	Week2,4,8,12	After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting triglycerides (TG), from baseline;
Percentage change of fasting HDL-C from baseline;	Week2,4,8,12	After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting high-density lipoprotein cholesterol (HDL-C) from baseline;
Cmax of HSK31679 (All subjects)	up to 2,4,7 weeks
The proportion of patients with MRI-PDFF decreased by > 30%	Baseline and Week 12	After 12 weeks of treatment, the proportion of patients with MRI-PDFF decreased by \> 30%;
AUC0-τ of HSK31679 (All subjects)	up to 2,4,7 weeks
Percentage change in fasting LDL-C from baseline;	Week2,4,8	Percentage change in fasting low-density lipoprotein cholesterol (LDL-C) from baseline after 2, 4, and 8 weeks of treatment;
Percentage change of fasting TC from baseline;	Week2,4,8,12	After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting total cholesterol (TC) from baseline;
Percentage change in body weight from baseline	Baseline and Week 12	Percentage change in body weight from baseline after 12 weeks of treatment.

Trial Locations

Locations (1)

Beijing Tsinghua Changgung Hospital, Tsinghua University; 🇨🇳 Beijing, China